近日，基石藥業（蘇州）有限公司宣布，任命謝毅釗博士為公司臨床發展部高級副總裁兼首席轉化醫學官。謝博士擁有超過20年的全球
腫瘤藥物臨床研發經驗，他的加入將進一步加強公司管理團隊的能力，加強基石藥業在臨床開發的核心優勢，並鞏固公司在中國創新生物製藥公司中的領先地位。
基石藥業專注於開發及商業化創新腫瘤免疫治療及分子靶向藥物。作為高級副總裁兼首席轉化醫學官，謝毅釗博士將負責藥物從早期臨床直至概念驗證階段（POC）的臨床開發，並負責監管臨床生物標記物的開發和應用，以支持公司腫瘤藥管線的進一步拓展。謝博士對全球
腫瘤領域的深入研究將有助公司進一步加強其在臨床開發的核心優勢，並鞏固公司在中國創新生物製藥公司中的領先地位。
謝毅釗博士
2018年5月，基石藥業成功完成約2.62億美元B輪融資，打破當時中國生物醫藥領域史上最大單筆B輪融資紀錄。目前，基石藥業
腫瘤管線中已有8個候選藥物處於臨床階段，包括4款處於或接近關鍵性試驗階段的候選藥物。其中，公司自主開發的中國第一個全人源全長抗PD-L1單克隆抗體CS1001正處於III期臨床試驗階段，有望成為中國上市的國內首批本土開發的PD-L1抗癌藥物之一。2018年6月，基石藥業先後與Blueprint Medicine和Agios達成獨家合作和大中華區授權許可協議，引入四個完成臨床概念驗證階段的產品，包括2018年7月獲得美國
FDA批准上市的ivosidenib，以及已進入全球III期
臨床試驗，預計將於2019年上半年提交美國上市許可申請的avapritinib。
江寧軍博士對此表示：「很高興看到謝毅釗博士帶著豐富的全球腫瘤研發經驗加入我們，謝博士在銜接臨床前和早期臨床階段的豐富經驗，有助提高公司管線藥物開發的整體成功率。作為基石藥業的首席轉化醫學官，他的領導力、專業能力以及廣泛的資源，對於公司實現在中國以及全球
腫瘤領域開發創新藥物的目標至關重要。」
加入基石藥業之前，謝毅釗博士曾擔任美國默克公司（在美國和加拿大之外稱為默沙東）腫瘤早期臨床研發部執行總監。在此之前，他曾擔任日本第一三共製藥公司腫瘤卓越策略團隊負責人。謝博士在美國紀念斯隆-凱特琳癌症中心（MSKCC）接受
腫瘤專科醫師培訓，並留任助理主治醫師及研究員。期間，他在MSKCC附屬的美國威爾·康乃爾醫學院擔任助理教授。
謝毅釗博士擁有美國南加州大學醫學博士及生物化學與分子生物學博士學位。
謝毅釗博士表示：「基石藥業建立強大豐富
腫瘤藥物管線的能力和臨床開發方面的速度令人興奮。我很榮幸加入這家潛力巨大的公司，並得以與經驗豐富的管理團隊合作，一起推動公司發展，讓中國乃至全球的癌症患者受益。」
備註：以上公告中英文如有歧義，一律以英文版本為準。以下為英文版本。
Dr. Tse's Extensive Track Record in Oncology Early Clinical Development Will Strengthen CStone's Core Competence as a Clinical Development Engine and Solidify CStone's Position among Leading Innovative Biopharma Companies in China
SUZHOU, China, December 10, 2018 – CStone Pharmaceuticals, a biopharma company focused on developing and commercializing innovative immuno-oncology and molecularly targeted drugs, announced today the
appointment of Archie Tse, M.D., Ph.D., as the newly established Senior Vice President, Chief Translational Medicine Officer (CTMO), reporting to Frank Jiang, M.D., Ph.D., Chairman and Chief Executive Officer. Dr. Tse has over 20 years of global oncology research and clinical development experience and will provide a strong addition to CStone’s senior leadership team.
In this role, Dr. Tse will be responsible for the development of assets at the early clinical development stage up to proof of concept (POC). He will oversee the development and implementation of clinical biomarkers to support progression of CStone’s pipelines. His in-depth understanding of the global oncology space will help further strengthen CStone’s core competence and solidify CStone’s position among leading innovative biopharma companies in China.
In May 2018, CStone successfully completed a USD 262 million financing round, which was the largest Series B funding in the history of China biopharma industry at the time. Currently, CStone has eight clinical stage assets with four at or near registration trial. CS1001, China’s first fully human, full-length anti-PD-L1 monoclonal antibody developed by CStone, has initiated Phase III clinical studies, and will potentially become one of the first locally-developed anti-PD-L1 cancer drugs launched in China. In June 2018, CStone announced exclusive collaboration and license agreements with Blueprint Medicine and Agios. With these two deals, CStone in-licensed four post proof of concept assets, including ivosidenib, which received US
FDAapproval in July 2018, and avapritinib, which has entered global Phase III clinical studies and expects to file a US marketing
application in H1 2019.
「We are thrilled to have Dr. Tse join the team and bring his profound global oncology research and clinical development experience,」 said Frank Jiang, M.D., Ph.D., 「Archie is highly experienced in bridging preclinical and early clinical phases to improve overall success of drug development. As CStone’s CTMO, his leadership, expertise and extensive network are critical in helping us advance toward our goal of developing innovative drugs in China and global oncology space.」
Prior to joining CStone, Dr. Tse was the Executive Director of Global Oncology Early Development at Merck (known as MSD outside of US and Canada). Before that, Dr. Tse served as the leader of the Oncology Team of Excellence for Strategy in Therapeutic Area at Daiichi-Sankyo. Dr. Tse is a board-certified medical oncologist trained at the US Memorial Sloan Kettering Cancer Center (MSKCC) where he stayed on to become a faculty as Assistant Physician and Assistant Member. In that period, he was also an Assistant Professor at the MSKCC affiliated Weill Cornell Medical School.
Dr. Tse obtained his M.D. and Ph.D. in Biochemistry & Molecular Biology from the University of Southern California, United States.
「I am very impressed by CStone’s remarkably rapid progress in the establishment and clinical development of its broad oncology portfolio,」 Dr. Tse said. 「It is a great honor for me to join this promising company and work with its seasoned management team to drive the Company’s growth for the benefit of cancer patients in China and worldwide.」
關於基石藥業/About CSTONE
基石藥業為滿足癌症患者需求而生，專注於開發及商業化創新腫瘤免疫治療及分子靶向藥物。成立2年多以來，公司已集結世界級的管理團隊，在臨床前研究、臨床開發以及商業化方面擁有豐富經驗。通過內部研發與外部合作組成的雙重創新來源，公司已構建起擁有14種候選藥物的強大抗腫瘤藥管線，包括4個為Blueprint Medicine與Agios製藥獨家合作和授權產品，與自研管線一起具有單一及聯合療法的巨大潛力及協同效應。在研候選藥物中，4款正處於或接近關鍵性試驗階段。基石藥業的業務模式由臨床研發驅動，並同時快速建立商業化及生產能力。公司目前受到知名投資者的支持，A輪與B輪融資額皆打破當時生物醫藥領域融資記錄，兩輪融資額共計4.12億美元。在經驗豐富的團隊、具有潛力的研發管線、強大的業務模式和可持續的資金支持下，基石的願景是通過為全球癌症患者帶來創新差異化
腫瘤療法，成為全球知名的領先中國生物製藥公司。